Large vessel vasculitis associated with atezolizumab.

Immune checkpoint inhibitors have become the cornerstone in the management of a variety of cancers and have been implicated in immune-related rheumatological adverse events, including inflammatory myositis, polyarthritis and vasculitis. Existing literature has documented large vessel vasculitis in association with ipilimumab, pembrolizumab and nivolumab therapy. Although large vessel vasculitis was reported in one patient who had received both atezolizumab and pegfilgrastim, our patient represents the first instance of large vessel vasculitis associated with atezolizumab alone. Discontinuation of atezolizumab and tapered glucocorticoid therapy resulted in clinical and radiographic resolution.